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INTRODUCTION
1. INTRODUCTION
  Tuberculosis is a ubiquitous, highly contagious chronic granulomatous bacterial
infection caused by the Mycobacterium tuberculosis. Mycobacterium tuberculosis is rod
shaped bacteria called as Koch’s bacillus. Tuberculosis is the world’s commonest cause
for  death  after  HIV/AIDS
.  
According  to  WHO  about  1/3rd of  world  population  are
infected with TB. More than 8 million people are commonly infected with TB annually in
developing countries like sub- Saharan Africa and Asia.1 The prevalence of TB in India
accounts for 30% of global burden and when combined with cases from china constitute
40% of all cases globally. Approximately 10% of the infected people develop active TB.
 TB spreads through droplets of secretions such as sputum or aerosols released by
coughing from the infected persons. Its eradication requires prevention, early diagnosis
and effective treatment of the infection. A vaccine called BCG is administered in many
parts of the world where TB is common.
 WHO and IUALTD recommended use of fixed dose combination of anti- T.B
drugs because FDC reduce the number of tablets to be consumed and thereby increase the
patient  compliance.2 Thus  FDC plays  a  major  role  in  preventing  emergence  of  drug
resistance.
  Widely used FDC for treatment of TB is rifampicin, isoniazid, ethambutol and
pyrazinamide.Treatment  of  TB involves  administration  of  combination  of  rifampicin,
isoniazid, pyrazinamide and ethambutol for initial 2 months followed by rifampicin and
isoniazid for 4 months.3  Isoniazid and rifampicin are the most potent anti-TB drugs kills
more than 99% tubercular bacilli within 2 months of initiation therapy.4
Rifampicin  is  a  critical  component  in  the  therapeutic  armamentarium  for
tuberculosis Rifampicin is a semi synthetic derivative of macro cyclic antibiotic derived
from  Streptomyces  mediterranei. Rifampicin  act  by  inhibiting  DNA dependent  RNA
polymerase. The bioavailability of rifampicin in FDC may be reduced owing to chemical
reaction  with  isoniazid  in  acidic  gastric  environment;  pyrazinamide  and  ethambutol
catalyses the reaction.5
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 Rifampicin  in  the  presence  of  isoniazid  as  FDC  may  undergo  greater
decomposition in the acidic conditions of the stomach, as compared to when rifampicin is
administered alone. Thus less rifampicin will be available for absorption from FDC as
compared to rifampicin administered as separate formulation.6
Rifampicin gets  absorbed rapidly upon oral  administration on empty stomach.
Food and some antacids decreases oral absorption of Rifampicin. Rifampicin hydrolyses
to 3-formyl rifamycin in acidic medium and hydrolysis is accelerated in the presence of
isoniazid.  Two  major  problems  are  reported  with  rifampicin  and  isoniazid  FDC that
includes the impaired and fall in bioavailability of rifampicin from FDC formulations
with isoniazid and other problem is poor stability of rifampicin containing FDC7.  The
factors responsible for variation in bioavailability include changes in crystalline form,
drug  absorption  by excipients,  moisture  content  and  particle  size.  Stability  problems
include  changes  in  drug  strength  and  increase  in  degradation  product  and  gain  in
moisture.8
Many tropical countries have adverse environmental conditions, including high
temperature, humidity and intense light. Products usually sold in secondary packages in
shops  that  do  not  have  air  conditioning. 9  Hence  the  question  arises:  “should
pharmaceutical products in tropical countries be tested for stability using the combination
of temperature and humidity?”
Packaging also plays a role in affecting the stability of rifampicin. The primary
role of packaging is to protect the dosage form from the moisture and oxygen present in
the  atmosphere.  There  are  many types  of  packaging materials  such  as  glass,  plastic,
rubber, metal and paper. Plastic has become the most popular materials for packaging
pharmaceuticals because it is strong, light weight and reasonably inert. Solid dosage form
is  popularly  packed  in  blister  pack  and  strip  pack.10 Blister  is  a  multidose  container
consisting two layers, of which one is shaped to contain the individual doses and strip is a
multi-dose container consisting of two layers, usually provided with perforations suitable
for containing single dose of solid.
2
Previously  studies  were  carried  out  to  determine  the  stability  of  FDC  anti-
tuberculosis products in commercial packages under ICH/WHO accelerated conditions
(400C/75%  RH)  and  suggested  barrier  packaging  to  prevent  catalytic  role  in  the
interaction  between  isoniazid  and  rifampicin.3 In  another  study  conducted  in  similar
conditions, it has been reported that strip products are more stable while blister products
showed both physical and chemical changes.11  Though marketed products of FDC anti-
TB drugs in strip or blister packages are considered stable based on the data obtained
from the official guide lines that recommend accelerated stability studies and ICH/WHO
accelerated conditions (400C/75% RH), in actual package the storage of these products in
the retail outlet at recommended conditions of storage are often overlooked and as such
bioavailability of these products particularly rifampicin is questionable. It is necessary to
examine whether these products in their original package are stable at varied temperature
and humidity conditions.
To  ensure  their  bioavailability  as  claimed  by  pharmaceutical  manufacturer,
therefore the present study aimed to investigate the stability of rifampicin from FDC
marketed  products  available  in  strip  and  blister  packages  by  exposing  them  400C,
400C/75% RH and to room temperature at 300± 20C for 60 days. The study may help to
understand the influence of packages on the stability of rifampicin from FDC products
when storage guidelines are over looked.
3
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LITERATURE
2. REVIEW OF LITERATURE
Tuberculosis is one of the most chronic and infectious disease occurring world
wide ranging from developing countries to developed countries. Tuberculosis infection is
caused by Mycobacterium tuberculii. Mycobacterium tuberculii is gram positive aerobic
rod shaped acid fast bacillus. This Mycobacterium tuberculii was discovered by Robert
Koch in 24th march in 1882 and named it as Koch’s bacillus. 12Primary infection is usually
asymptomatic or latent with the development into lungs.
CLASSIFICATION OF ANTI-TUBERCULOSIS DRUGS:
Anti-Tuberculosis drugs are classified as:
   1 .FIRST LINE GENERATION         : First line class of drugs includes rifampicin, 
                                                                 Pyrazinamide, ethambutol and isoniazid.  
   2. SECOND LINE GENERATION   : Second line class of drugs includes amikacin 
and ethionamide                                 
3. THIRD LINE GENERATION     : Third line class include thioacetone, arginine,
macrolide and vitamin D
GENERALLY TWO TB RELATED CONDITIONS EXIST:          
LATENT TUBERCULOSIS
People with latent TB are not sick because the TB germs in the body are not active.
The often prescribed medicine to  prevent  them from being infected  by TB is  giving
isoniazid for 9 months.
ACTIVE TUBERCULOSIS
4
This kind of TB occurs when the immune system is not capable of defending the
infection.  When Mycobacterium tuberculii  are  active,  it  is  called  active  tuberculosis.
Rifampicin, isoniazid, ethambutol and pyrazinamide are the preferred dosage regimen for
this kind of Tuberculosis.
2.1 EPIDEMOLOGY OF TUBERCULOSIS
Tuberculosis is the major cause of mortality and morbidity in many undeveloped
countries  like Latin America,  Asia and Africa.  National  institutes of health  of United
States reported that about 17 billion people of world population are infected with TB
annually. Of all these people infected with mycobacterium tuberculosis, about 5% will
develop active TB disease and other 95% people will develop a latent infection that may
later progress to cause disease depending upon the status of immune system.13
There are several  reasons for increasing incidence of tuberculosis with current
increase  in  cases  of  HIV.   Part  of  reason  is  the  development  of  multi  drug  resistant
tuberculosis  mutants.  Globally  South  East  Asia  accounts  for  the  maximum  of  33%
incidence  of  TB. This  burden  is  increased  by human immunodeficiency virus  (HIV)
infection, which impairs the immune system and allows large numbers of people already
infected with tuberculosis to progress to active disease.
In South Africa around 10,000 people are infected with tuberculosis annually.    In
a view of  severity and spread of  disease in 1993 W.H.O declared TB to  be a  global
emergency.  In  2002  World  Health  Organization  (W.H.O)  notified  49,656  patients  in
Thailand  (WHO  Report  2004)  and  6,906  deaths  (Health  information  Group,  2003).
250,000 deaths were due to TB/ HIV co-infection. WHO estimates 460,000 multi drug
resistant-TB cases occur each year.
The most populated countries of Asia have the largest number of cases:  India,
China, Indonesia, Bangladesh and Pakistan together accounts for more than half of global
burden. There were 22 high burden countries, including Thailand that W.H.O particularly
noticed.  It is feared that by 2020 about 200 million individuals will become sick and 70
million people will die in the developed countries.14
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In a view to control TB W.H.O and IUALTD recommended a strategy for TB
control and named it as DOTS (Directly Observed Therapy). Every year W.H.O spends
billions  of  dollars  in  the  issue  of  TB  control.  According  to  South  African  National
Tubercular Association (SANTA) DOTS spend 130 million US dollars in South Africa
for curing TB in 1998.  BY the proper use of DOTS 500 million U.S dollars will be saved
in  South  Africa  annually.15 DOTS have  been  introduced  in  Thailand  since  1996,  the
patient rate reduced after by applying DOTS therapy.
 2.2 FIXED DOSE COMBINATIONS
Combination therapy refers to treatment with two or more drugs administered at
one time to ensure patient compliance to combine the requisite drugs physically into one
preparation is known as fixed dose combination. 16
ADVANTAGES: 
• Better patient compliance.
• Less chances to develop drug resistance.
• Simplicity of treatment with minimal prescription errors
DISADVANTAGES:
• Young children may receive higher dose than required.
• FDC is more expensive than individual components in terms of cost per tablet.
Fixed dose combinations from the who model list of essential medicines
6
Table 1: Fixed dose combinations from the WHO model list of essential        medicines
W.H.O and IUALTD recommend use of fixed dose combinations. Anti-TB drugs
are generally given in the form of fixed dose combinations. Anti-TB FDC formulations
combine two or more first line anti-TB drugs like rifampicin, isoniazid, ethambutol and
pyrazinamide of fixed proportion in a single dosage form.2 The recommended strength for
fixed dose combinations by WHO is rifampicin 150mg, isoniazid 75mg, pyrazinamide
400mg and ethambutol 275mg.
Treatment of TB involves rifampicin, isoniazid, ethambutol and pyrazinamide for
initial  2 months  followed by administration of rifampicin and isoniazid for 4  months
which  act  on  mycobacterium  tuberculii  by  varying  methods  including  sterilization,
bacteriostatic  and  bactericidal.17 Rifampicin  and  isoniazid  are  the  most  powerful
7
bactericidal drugs against all strains of TB bacilli. Ethambutol is used in combination
with  powerful  drugs  to  prevent  emergence  of  resistant  to  bacilli.  Rifampicin  act  by
inhibiting  DNA –  dependent  RNA polymerase  by  blocking  RNA transcription.  The
problem involved in the FDC is poor bioavailability of rifampicin. The reason for poor
bioavailability of rifampicin is change in crystalline form of rifampicin, drug adsorption
by excipients and formulation factors. 8 
Isoniazid  is  a  synthetic  antimycobacterial  and  bactericidal  agent  for  both
extracellular and intracellular organism and act by interfering with cell wall mycolic acid
synthesis.Pyrazinamide exhibits invitro bactericidal activity. 18
2.3 DEGRADATION OF RIFAMPICIN:
Degradation  of  rifampicin  is  PH  dependent.  In  acidic  medium  rifampicin
hydrolyses to 3-formylrifamysin and it  undergoes air  oxidation in alkaline medium to
form  inactive  quinine  derivative  and  rifampinquinone.  3-formylrifamysin  (3FRSV)
precipitates in acidic conditions and the formation of 3- formylrifamysin in the acidic
environment  of  stomach  is  the  important  factor  affecting  bioavailability.7  An elegant
mechanism to explain the increased degradation of rifampicin in presence of isoniazid is
19
Rifampicin + H20                        3 FRSV + 1- amino 4-methyl piperazine
Isoniazid + 3- FRSV                    Isonicotyl hydrazone + H20
Rifampicin hydrolyses to 3 FRSV. Isoniazid reacts with 3-FRSV in a reversible
manner where the forward reaction is faster second order reaction and backward reaction
is slower first order reaction.
The  overall  reaction  is  favored  towards  formation  of  hydrazone  and  thus  an
overall  increase in  degradation of rifampicin to  3- FRSV is  observed the same time,
hydrazone are known to  hydrolyze in  the acidic medium resulting in  regeneration of
isoniazid and 3-FRSV.20
8
The decomposition of rifampicin in acidic conditions in absence of isoniazid stop
the  formation  of  3-formylrifamysin  but  in  the  presence  of  isoniazid,  the  reaction  is
proceeded  to  form  hydrazone  between  3-  formylrifamysin  and  isoniazid  resulting
recovery  of  isoniazid  but  eventually  causing  loss  of  rifampicin.  This  indicates  that
isoniazid  remains  unaffected  and  plays  a  role  of  a  catalyst  in  the  degradation  of
rifampicin  in  acidic  conditions  to  3-FRSV. (4,  21) This  explains  the  reason  why  the
bioavailability problem is confined to rifampicin alone but not to isoniazid.
          In acidic medium 12.4% of rifampicin alone is degraded to 3-formyl rifamycin
within 1 hour and in the presence of isoniazid degradation of rifampicin is increased to
21.5%. This indicate that degradation of rifampicin to 3-formylrifamysin is almost twice
and two times faster in the presence of isoniazid than that of rifampicin alone.
2.4 METHODS ADOPTEDTO PREVENT DEGRADATION OF RIFAMPICIN:
           Approaches to prevent degradation of rifampicin include enteric coating of solid
formulations or drug granules, use of alkaliniser at the time of administration of FDC
formulations,  exploitation  of  formulation  factors  including  addition  of  additives  and
segregation of delivery of rifampicin and isoniazid.
            The following approaches seem plausible. (i) Enteric coating of solid formulations
or  drug  granules.  (ii)  Use  of  alkaliniser  at  the  time  of  administration  of  FDC
formulations. (iii) Exploitation of formulation factors, including addition of additives.8 A
novel formulation comprising of rifampicin and sodium lauryl sulphate prepared by co-
grinding method, proved effective to minimize the degradation of rifampicin in acidic
environment by its retarded release pattern. This segregation release pattern of rifampicin
in  alkaline  environment  and  isoniazid  in  acidic  environment  of  GI  tract  prevents
degradation of rifampicin alone and its interaction with isoniazid.22
2.5 STABILITY STUDIES:
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         Stability is the capacity of drug to remain within specifications established to ensure
its identity, strength, quality and purity. The purpose of pharmaceutical stability testing is
to provide evidence on how the drug substance or drug product varies with time under the
influence of variety of environmental factors such as temperature, humidity and light.
Stability testing includes long term stability studies, intermediate stability studies
and accelerated stability studies. In long term stability study the product is stored at 250 C
± 20C/60% ± 5 RH for 12 months. In intermediate stability study the product is stored at
300C ± 20/65% ± 5% RH for 6 months and in accelerated stability studies the product is
stored at 400C ± 20/75% ± 5% RH for 6 months. 23
Table 2: The main objectives of stability testing are shown in the table below
Objective Type of study For use in
To select adequate (from the
view-point of stability)
formulations and container
closure
systems
Accelerated Development of
product
To determine shelf-life and
storage conditions
Accelerated and/or
long term
Development of
product and
registration dossier
To substantiate the claimed
shelf-life
Long term Registration dossier
To verify that no changes
have
been introduced in the
formulation or
manufacturing
process that can adversely
affect
the stability of the product
Accelerated and/or
long term
Post approval
changes and
quality assurance in
general, including
quality control
Accelerated testing
10
Studies designed to increase the rate of chemical degradation or physical change
of a drug substance or drug product by using exaggerated storage conditions as part of the
formal stability studies. Data from these studies, in addition to long term stability studies,
can be used to assess longer term chemical effects at non-accelerated conditions and to
evaluate the effect of short term excursions outside the label storage conditions such as
might occur during shipping .24
Stability  problems  include  change  in  drug  strength,  increase  in  degradation
product,  gain  in  moisture  and  chemical  stability.(8) Chemical  stability  is  generally
expressed in  terms of rate  constant  (k)  representing either  product  formation or  drug
degradation. For any mechanism the rate of reaction (k) can be described by general rate
equation. 25
dα /dt = kf (α)
α = conversion of reaction
f (α) = the  conversion function
For zero order  reaction the reaction rate  is  independent  of  drug concentration
while for the first order reaction the rate depends linearly on drug concentration.
Zero order       dα/dt = k
First order        dα/dt = k (α)
Temperature dependence on the rate constant, k is usually expressed by Arrhenius
equation 
                                                     K= Ake - Eα/RT
                                            A = Pre exponential factor
 Ea = Activation energy (cal/mole)
T= absolute temperature
R = gas constant
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Chemical  instability  of  fixed  dose  combination  is  found  to  occur  due  to  two
reasons.  One  is  direct  interaction  of  rifampicin  and  isoniazid;  the  mechanism which
involves interaction of imine group of rifampicin with amino group of isoniazid to yield
hydrazone in solid formulation environment. The other reason is creation of an acidic
hydrolytic environment upon moisture gain by ethambutol  hydrochloride.  The two co
drugs  present  usually  in  fixed  dose  combinations  accelerate  the  reaction  between
rifampicin and isoniazid.5
HUMIDITY: 
Humidity can have on effect on solid drug substances. Pharmaceutical solid forms
may contact  with moisture during manufacturing process and storage at  high relative
humidity. The amount of moisture that is sorbed is dependent on the chemical properties,
temperature,  relative humidity and porosity of the packaging material.  The excipients
used in solid dosage form affect the stability of the formulation. The more amorphous is
used in formulation the more water is sorbed. 26
PACKAGING:
The primary role of packaging is to protect the dosage form from the moisture and
oxygen present in the atmosphere. There are many types of packaging materials such as
glass, plastic, rubber, metal and paper. Plastic has become the most popular materials for
packaging pharmaceuticals because it is strong, light weight and reasonably inert. Solid
dosage form is popularly packed in blister pack and aluminum foil.
Two  major  factors  which  affect  packaging  are  leachable  impurities  and
permeability of moisture and oxygen. Two blister packs one with polyvinylchloride and
another  with  polyvinyl  chloride  and  laminate  of  polymonochlorotrifluroethylene  were
backed with impermeable foil and used for packing. It was found that polyvinyl chloride
laminated with polymonochlorotrifluroethylene blister pack could protect  solid dosage
form better than the other.10
2.6 TB DRUGS IN DEVELPOMENT:
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The  recent  discovery  of  diarylquinone  is  a  promising  TB  drug  that  shortens
therapy. Andries et.al identified diarylquinoline compound which is highly active against
Mycobacterium tuberculosis.
Flouroquinolines 
These are broad spectrum of antibiotics currently used as second line drugs in TB
therapy. Moxifloxacin and Gatifloxacin are fluroquinolines.27 that has longer half life and
more active against mycobacterium tuberculosis than ofloxacin. Moxifloxacin has been
shown to kill a sub population of tubercle bacilli that has not been killed by rifampicin.
Moxifloxacin  in  combination  with  rifampicin  and  pyrazinamide  kills  bacteria  more
effectively than standard regimen of INH +RIF + PZA
Rifampin derivative:
Rifampin  derivatives  include  rifapentine 28,  rifabutin  and  rifalazil.  Rifalazil  is
highly  active  against  a  range  of  intracellular  bacteria  including  mycobacterium
tuberculosis.
Oxazolidones:
These are active against gram positive bacteria. This oxazolidones inhibit protein
synthesis at an early stage by binding to 23s rRNA of the 50s ribosomal unit.29
Nitroimidazopyran:
It acts by inhibiting mycolic acid which is the main component of cell wall and
protein synthesis.30
H.Bhutani et.al, 3 (2003) carried out a study to determine the physical  and chemical
stability of anti- tuberculosis fixed dose combination products under accelerated climatic
conditions. In this study fixed dose combinations of rifampicin, isoniazid, pyrazinamide
and  ethambutol  products  were  stored  for  3  months  under  ICH/WHO  accelerated
conditions (40/75% RH) with and without original packaging in the presence and absence
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of light.  The unpackaged products underwent both physical  and chemical  changes.  A
significant  finding  is  that  pyrazinamide  and  ethambutol  play  a  catalytic  role  in  the
interaction between isoniazid and rifampicin. This study suggested that unless fixed dose
combinations are packed in barrier packaging, anti-tuberculosis fixed dose formulations
are  considered  as  unstable  and  consideration  should  be  given  to  their  development,
packaging and stability testing.
S.Singh  et.al, 31 (2003)  conducted  study  on  pilot  stability  study  on  four  fixed  dose
combination  anti  tubercular  products  at  400C and  75% RH.  The strip  products  were
stable, while blister products showed both physical and chemical changes. The products
in unpacked conditions showed severe  ( 60 )  decomposition of rifampicin and the
main decomposition product  is  isonicotylhydrazine of  3-  formylrifamysin.  This  study
suggested that attention should be paid to the detection and quantitation of the product in
marketed  formulations.  The  packaging  material  used  in  manufacturing  of  fixed  dose
combination products should also be of highest quality.
Saranjit Singh, et.al  8  2001has given critical review of probable reasons for the poor/
variable  bioavailability  of  rifampicin  from  anti-tuberculosis  fixed  dose  combination
products and likely solutions to the problems. Unfortunately the origin and cause of the
problem is not clearly understood though the GMP and crystalline changes are cited as
the  principal  reasons.  The  enhanced  decomposition  of  rifampicin  in  the  presence  of
isoniazid in stomach after ingestion is indicated as the key factor behind the problem.
C.J Shishoo et.al, 6  (2001) conducted study on impaired bioavailability of rifampicin in
the presence of isoniazid from fixed dose combination. Bioavailability of rifampicin after
administration of single component rifampicin (450 mg) capsule and rifampicin-isoniazid
(RIF-INH) (450+300mg) single dose is  noted.  Cross-over  test  were conducted on six
healthy male  volunteers  and  HPTLC method  was  developed  to  know the  amount  of
Rifampicin and its metabolite ,25-Desacetylrifampicin in urine. Significant decrease in
bioavailability of rifampicin from fixed dose combination capsules was observed. This
bioavailability study confirmed that stability of rifampicin in the presence of isoniazid in
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acidic environment of stomach is the main factor for reduced bioavailability of rifampicin
from RIF-INH combination formulations. This study underlines the fact that there is a
urgent need to reconsider the formulation of fixed dose combination products in order to
minimize or avoid the decomposition of rifampicin in gastrointestinal tract
C.J Shishoo  et.al,  7 (1999) conducted study on  stability of  rifampicin in  dissolution
medium in presence of isoniazid. Rifampicin (RIF) hydrolyzes in acidic medium to form
insoluble and poorly absorbed 3-Formyl rifamycin SV (3-FRSV). This study describes
development  of  two  principally  different  methods,  Dual  Wavelength  UV–
Vis.spectrophotometry (DW spectrophotometer) and HPTLC, to determine 3-FRSV in
presence of RIF Using DWspectrophotometry, RIF was estimated by using wavelengths
475.0 and 507.0 nm and 3-FRSV was estimated using 457.0 and 492.0 nm. Both the
methods were found to be specific,  accurate and reproducible.  The proposed methods
were successfully applied to  determine  the rate  of  degradation of  RIF to  3-FRSV in
dissolution  medium  (0.1  N  HCl)  and  also  two  times  stability  of  RIF  in  market
formulations of RIF and RIF with INH in dissolution in presence of isoniazid (INH). The
rate of degradation of RIF in presence of INH was almost two times more than that of
rifampicin  alone  medium.  It  has  more  than  that  of  RIF  alone.  These  methods  were
utilized  to  study the  stability of  rifampicin  in  market  formulations  of  rifampicin and
rifampicin with isoniazid.
 It has been observed that RIF degrades by 12.4% to form 3-FRSV (RIF formulations)
while  in  presence  of  INH  the  degradation  is  catalyzed  to  about  21.5%  (RIF_INH
formulations),  in  45  min.  Thus,  lower  concentration  of  RIF  may  be  available  for
absorption  leading  to  poor  bioavailability  of  RIF  from  combination  dosage  forms
(RIF_INH) as compared to formulations containing only RIF. It is proposed that specific
analytical method should be used to measure RIF in presence of dissolution medium.
Hemant Bhutani et.a,l5 (2005) conducted a study to know the Mechanistic explanation
to the catalysis by pyrazinamide and ethambutol in the reaction between rifampicin and
isoniazid in anti-TB FDCs. Rifampicin and isoniazid are known to interact with each
other in solid formulation environment to yield isonicotinyl hydrazone (HYD). In earlier
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studies,  this  reaction  was  indicated  to  be  catalyzed  by pyrazinamide  and  ethambutol
hydrochloride, the two other co-drugs present in anti-tuberculosis fixed-dose combination
(FDC) formulations. The present study was carried out to understand the catalytic role of
pyrazinamide  and  ethambutol  hydrochloride  on  the  reaction  between  rifampicin  and
isoniazid. Organic bases and amides similar in structure to pyrazinamide and ethambutol
hydrochloride were combined individually with rifampicin and isoniazid. The compounds
employed  were  pyrazine,  piperdine,  pyrollidine,  pyridine,  triethylamine,
diisopropylethylamine,  picolinamide,  benzamide,  ethylenediamine,  ethanolamine,
diethanolamine, and triethanolamine. An additional study was carried out in the presence
of free base of  ethambutol.  These mixtures  were exposed to accelerated stability test
condition  of  400 C/75%  RH  for  15  days.  The  drugs  showed  different  extent  of
degradation, yielding HYD, and in some cases degradation products of rifampicin. The
results confirmed the catalytic role of pyrazinamide and ethambutol hydrochloride. The
catalysis is postulated to involve intra molecular proton transfer during transhydrazone
formation process, entailing a tetrahedral mechanism.
Shrutidevi Agrawal et.al, 32  (2004) conducted a study on Dissolution test as a surrogate
for quality evaluation of rifampicin containing fixed dose combination formulations.  Six
FDC formulations were used in this study, of which four had passed bioequivalence while
two  failed.  Formulations  showed  variable  dissolution  at  different  conditions  and
dissolution  at  50  rpm  was  most  sensitive  and  differentiated  the  release  profiles  of
rifampicin under various pH conditions. It was possible to predict in vivo performance of
rifampicin  from  FDCs  when  in  vitro  rate  and  extent  of  release  at  various  pH  was
correlated with site, pH and concentration dependent absorption of rifampicin along with
gastric emptying time. It was also seen that dissolution conditions recommended in USP
for different types of FDCs were insensitive for the formulation changes. Based on this
comprehensive evaluation, a decision tree was proposed which will act as a guideline for
quality  evaluation  of  FDC  products  and  also  provide  a  fundamental  knowledge  for
optimization of formulations failing in dissolution studies.
Satish  Balkrishna  Bhise  et.al, 22 (2007)  formulated  and  evaluated  novel  fixed  dose
combination  of  anti-tuberculosis  drugs. The  solid  mixtures  of  rifampicin  and  sodium
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lauryl  sulphate  were  prepared  at  molar  ratio  of  1:1  by co-grinding  method.  In  vitro
dissolution studies were carried out in 0.1N HCl and phosphate buffer  pH 6.8.  Solid
mixtures  prepared  by  co-grinding  method  were  found  to  be  useful  in  delaying  the
dissolution of rifampicin in acidic medium .The release of rifampicin from novel fixed
dose combination formulation was 0% in 0.1N HCl up to two hours and faster release
within 15 minutes in alkaline pH was achieved, while Isoniazid was released completely
within  20  minutes  in  0.1  N HCl.  A novel  formulation  comprising  of  rifampicin  and
sodium lauryl sulphate, prepared by co-grinding method proved effective to minimize the
degradation of rifampicin in acidic environment by its retarded release pattern. Thus this
approach  is  beneficial  for  the segregation of  release  pattern of  rifampicin in  alkaline
environment and isoniazid in the acidic environment of the GI tract, which will lead to
prevent the degradation of rifampicin alone & its interaction with isoniazid.
Mukesh C. Gohel et.al,33  (2007) developed a novel solid dosage Form of Rifampicin and
Isoniazid With improved functionality to minimize degradation of rifampicin in acidic
medium and to modulate the release of rifampicin in the stomach and isoniazid in the
intestine.  Gastro  retentive  tablets  of  rifampicin  (150  mg)  were  prepared  by  the  wet
granulation  method.  Hard  gelatin  capsules  (size  4)  containing  a  compacted  mass  of
isoniazid (150 mg) and dicalcium phosphate (75 mg) were enteric coated. Two tablets of
rifampicin and 1 capsule (size 4) of isoniazid were put into a hard gelatin capsule. The in
vitro drug release and in vitro drug degradation studies were performed. Rifampicin was
released over 4 hours by zero-order kinetics from the novel dosage form. More than 90%
of isoniazid was released in alkaline medium in 30 minutes. The results of dissolution
studies revealed that a substantial amount of rifampicin was degraded from the immediate
release capsule containing rifampicin and isoniazid powder owing to drug accumulation
in  the  dissolution  vessel  and  also  to  the  presence  of  isoniazid.  The  degradation  of
rifampicin to 3-formyl rifampicin SV (3FRSV) was arrested (3.6%-4.8% degradation of
rifampicin at 4 hours) because of the minimization of physical contact between the 2
drugs and controlled release of rifampicin in acidic medium. This study concludes that
the problem of rifampicin degradation can be alleviated to a certain extent by this novel
dosage formulation
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Y. Ashokraj  et.al, 34 (2006) conducted a study on Quality control of anti-tuberculosis
FDC formulations in the global market. Accelerated stability studies were perform  to
determine the quality and performance of rifampicin containing fixed dose combination
formulations  with respect to physical, chemical and dissolution properties at (400C / 75%
RH). All the formulations were found to be stable where extent of dissolution was within
10% of that of initial volume and all formulations passed the pharmacoepial limits for
assay  and  content  uniformity.  The  study  revealed  that  good  quality  of  rifampicin
containing  FDC  that  remain  stable  after  6  months  accelerated  stability  testing  are
available in market place.
2.7 BACK GROUND OF REVIEW:
This study reveals the importance of carrying out the accelerated stability studies
on marketed products of anti-tubercular FDC products containing rifampicin, isoniazid,
pyrazinamide and ethambutol. From  the previous study it was found that unpackaged
FDC  products undergo degradation more when compared to packaged FDC products and
it also revealed that type of packaging also has influence on the stability and concluded
that  blister  packs  undergo more degradation when  compared to  strip  packaging.31  By
considering all these factors the present study was focused  to carry out the accelerated
stability  study  on  marketed  products  of  anti-tubercular  FDC  containing  rifampicin,
isoniazid, ethambutol and pyrazinamide at different temperatures like 40C, 250C and at
400C with 75% RH for  60days  and  to  determine  the  amount  of  rifampicin  that  gets
degraded from marketed FDC products containing rifampicin, isoniazid, ethambutol and
pyrazinamide.
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AIM & OBJECTIVE
3. AIM AND OBJECTIVE
The aim of the present work is to carry out the accelerated stability study on
four marketed products of anti-tubercular fixed dose combinations containing same dose
of rifampicin, isoniazid, ethambutol and pyrazinamide at different temperatures like 40C,
250C and at 400C with 75% RH for 60days and to determine the amount of rifampicin
that get degraded from four marketed fixed dose combination products.
OBJECTIVE:
The objective of the present study is as follows
 To know the amount of rifampicin that gets degraded from marketed fixed dose
combination product
 To select a better package for anti-tubercular fixed dose combination products that
minimize degradation
 To choose a better formulation from the four different marketed fixed dose   
combination products.
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4. PLAN OF WORK
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PROFILES
5. DRUG PROFILE
5.1 RIFAMPICIN: 
               Rifampicin is a semi synthetic antibiotic derivative of rifamycin group.
Compound is derived from Amycolatopsis rifamycinica.
Structure       :
                                          
                                             Rifampicin
Empirical Formula          :         C43H58N4O12
Molecular weight             :         822.94
Chemical name                                         
3-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin  or  5,6,9,17,19,21-
hexahydroxy - 23 - methoxy - 2,4,12,16,20,22 - heptamethyl - 8 - [N - (4 - methyl - 1
-piper-azinyl)formimidoyl] - 2,7 - (epoxypentadeca - [1,11,13]trienimino)naphtho[2,1 -
b]furan - 1,11(2H) - dione 21-acetate
Physical and chemical properties
Appearance                    :             Red brown powder
Melting point                 :             183 – 1880C
Dose                                :             10mg/kg body weight in daily treatment
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Solubility 
Slightly soluble  in  water,  soluble  in  ethylacetate  and  methanol  and  freely soluble  in
chloroform. 35
Mechanism of action 36
Rifampicin  act  by  inhibiting  DNA  dependent  RNA  polymerase  activity  in
susceptible cells. Rifampicin interacts with bacterial RNA polymerase but doesn’t inhibit
mammalian enzyme. At therapeutic levels, rifampin has bacterial activity against  both
intracellular  and  extracellular  mycobacterium  tuberculosis.  Bacterial  resistance  to
rifampin is caused by mutations leading to change in the structure of β subunit of RNA
polymerase.
PHARMACOKINETICS 
Absorption 
 It is well absorbed from the gastrointestinal tract. Peak plasma concentration is
attained within 1.5 to 4 hours after oral administration. Absorption is reduced to 30%
when the drug is ingested with food.
Distribution 
Rifampicin  is  widely  distributed  in  to  all  most  all  body  tissues  and  fluids
including cerebrospinal fluid barrier. About 90% of rifampicin binds to plasma proteins. 37
Rifampicin has high degree of placental transfer with a foetal to maternal serum level
ratio of 0.3. 
Volume of distribution         :             1.6 Liter / kg
Biological half life                 :             3 to 5 hours 
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Metabolism
It  is  metabolized  by  liver  microsomal  enzymes  its  active  metabolite  is
deacetylrifampicin. Formyl rifampicin is urinary metabolite that forms in urine. 
Elimination
Rifampicin gets rapidly eliminated in bile and 30% of dose gets eliminated in
urine in unchanged form and around 60% of oral dose is excreted in faeces.
Drug interactions 38
1. Antacids containing aluminum hydroxide reduce the bioavailability of rifampicin
2. Isoniazid and rifampicin interaction has lead to hepatotoxicity
3. Presence of food decreases the absorption of rifampicin
4. Barbiturates and salicylates decrease  the activity of rifampicin
5. Para- amino salicylic acid granules delay rifampicin absorption
Adverse effects
1. Acute haemolytic anemia, hypersensitivity
2. Diarrhoea , peripheral neuritis and vomiting
3. Severe gastrointestinal side effects, rash , chills and fever
4 .Edema, dermatitis
5. Opthalamic use of rifampicin causes irritation to eyes and ocular pain
Use                          :          Used in the treatment of tuberculosis
Storage                   :           Stored in well closed container
5.2 ISONIAZID
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Isoniazid was synthesized in 1912 at the German University of Prague by Meyer and
Mally(39)
STRUCTURE                           
                                       
                                            Isoniazid
Empirical formulae                       : C6H7N
Molecular weight                          : 137.14
Chemical name                             : Isonicotinic acid hydrazide
Physical and chemical properties 
Appearance              :  White crystalline powder
Melting point           :  170 - 174
Dose                         : 5mgh/kg body weight daily and 10 mg/kg body weight in thrice 
                                    Weakly treatment
Solubility                :  Freely soluble in water and sparingly soluble in alcohol (40)
Mechanism of action
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 Isoniazid kills actively growing tuberculii bacilli by inhibiting the biosynthesis of
mycolic acid which is the major component of cell wall of mycobacterium tuberculosis.
(41)
 At therapeutic levels isoniazid is bacterial against actively growing intracellular and
extracellular mycobacterium tuberculosis.
PHARMACOKONETICS 
Absorption 
90% of drug gets absorbed upon oral  administration and the presence of food
reduces the absorption. Time to attain peak plasma concentration is about 1 to 2 hours 
Distribution 
Isoniazid is  widely distributed to all  fluids  and tissues including cerebrospinal
fluid, pleural and ascetic fluids, skin, sputum, muscles and lungs. It crosses the placenta
and distributed in to breast and milk. Protein binding is very low about 10%.
Volume of distribution                 : 0.57 to 0.76 L/kg
Biological Half life                       : 1-5hours 
Metabolism 
Metabolism  occurs  by  liver,  isoniazid  is  acetylated  by  liver  in  to  active
metabolites  which  are  excreted  in  urine.  Acetyl  isoniazid  is  further  hydrolyzed  to
isonicotinic acid and acetyl hydrazine. Non acetylated isoniazid is excreted unchanged in
urine.
Elimination 
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5 to 30% of drugs get excreted by renal excretion. Slow acetylaters excrete 25%
to 66% of dose in urine as isoniazid and rapid acetylaters excrete 5 to 37% of dose in
urine.
Drug interactions 42
1. Concomitant use of acetaminophen and isoniazid cause nephrotoxicity
2.  Alaprozolam administration with isoniazid cause elevated plasma concentrations of
alaprozolam
3. Concomitant isoniazid therapy with BCG vaccine may inhibit efficacy of bcg vaccine
4. Antacids should not be administered with isoniazid
5. Administration of isoniazid with cycloserine cause increased CNS adverse effects
Adverse drug reactions 
1. Peripheral neuropathy (43), seizures
2. Psychosis, optic neuropathy (44) and metabolic acidosis
3. Hypocalcemia, scaling and eczema
4. Memory loss, gynecomastia and vitamin B6 deficiency
Use                :          Used in treatment of tuberculosis
Storage         :          Should protect from moist and light. Stored at 200C to 
          250C 
5.3 Pyrazinamide     
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 The synthesis of pyrazinoic acid, the active metabolite of pyrazinamide
STRUCTURE                              :
 
                                                           
                                                                  Pyrazinamide
Empirical formulae                      : C5H5N30
Molecular weight                         : 123.11
Chemical name                            : Pyrazine -2- carboximide
Physical and chemical properties (45)
Appearance                 :          White crystalline powder 
Melting point              :           1900C
Dose                             :           Orally 15 to 30 mg/kg once daily
Solubility                     :           Sparingly soluble in water
Mechanism of action 
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Pyrazinamide is a synthetic purine analog of nicotinamide and exhibits in vitro
bactericidal  activity  only  at  acidic  PH. (46) Pyrazinamide  is  quite  active  against
intracellular  bacilli  in  the  acidic  environment  of  macrophages.  Because  of  its  action
against intracellular bacilli, the organisms most likely to be responsible for relapse, it may
play an important  role in decreasing relapses.  Within tuberculous lesions,  it  has been
hypothesized  that  there  may  be  4  different  populations  of  tubercle  bacilli.  Due  to
variables in their environments within the body, these 4 populations may differ in their
metabolism and susceptibility to the ant tuberculosis drugs. One group of bacilli is felt to
be metabolically active (rapidly and continuously growing). This group of organisms is
believed  to  be  killed  readily by isoniazid,  Rifampin,  and  streptomycin  when  used  in
bactericidal doses. The second group of bacilli is thought to have intermittent spurts of
metabolic activity, during which time Rifampin is most capable of killing them. A third
group  of  bacilli  is  thought  to  be  found  in  acidic  environments,  such  as  within
macrophages.  Pyrazinamide  appears  to  be  especially  effective  against  this  particular
group. Pyrazinamide should be used only in combination with other ant tubercular drugs
in the treatment of M tuberculosis;  resistance develops rapidly (within 6 to 8 weeks)
when pyrazinamide is used alone. 
PHARMACOKINETICS 
Absorption 
When  given  orally  drug  is  completely  absorbed  from  gastrointestinal  tract,
absorption is not influenced by food intake. After oral intake of 1500mg of pyrazinamide,
a peak level is obtained; the time taken to reach peak serum concentration is decreased by
antacids concentration.
Distribution 
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Pyrazinamide has excellent penetration in to cerebrospinal fluid ranging from 87
to 105% of corresponding serum concentration.  Drug is  distributed to all  fluids,  bile,
kidney, liver and lungs. 31% of drug binds to plasma proteins.
Volume of distribution         :          0.57 to 0.74L/kg
Biological Half life                :          9 to 10 hours
Metabolism
Pyrazinamide is  hydrolised in liver to its  major active metabolite ,  pyrazonoic
acid  which  further  hydroxlated  to  main excretory product  5-  hydroxypyrazinoic  acid
.Approximately 1% to 14% of the drug is excreted as unchanged pyrazinamide, with the
remainder excreted as metabolites (Pyrazinoic acid, and 5-hydroxypyrazinoic acid). 
Elimination 
About 1 to 14% of drug excreted as unchanged pyrazinamide in urine, remaining
excreted as metabolites.
DRUG INTERACTIONS 
1. Allopurinol  increases  plasma  concentration  of  pyrazoic  acid  which  is  directly
responsible for renal urate secretion.
2.  Pyrazinamide  might  antagonistically effect  the  action  of  medications  that  have
uricosuric effect such as  acetylsalicylic acid and probencid.
3. A potentially serious interaction exist with zidovudine in combination therapy.
Adverse drug reactions 
1. Pellagra, thrombocytopenia and prophyria
2. Interference of metabolism of purine occurs
3. Arthralgia, hepatotoxicity47
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Use             :  Used in combination with anti- tubercular drug for 
                                              the treatment of tuberculosis
                      Storage       :  Stored in well closed container at controlled room
                                              temperature at 15-300                                           
5.4 ETHAMBUTOL
It  is  oral  chemotherapeutic  agent  specifically  active  against  actively  growing
micro organisms 
Structure:                            
Ethambutol
Empirical formulae         :      C10H24N2O2
                                   Molecular weight             :      277.23l
                                   Chemical Name               :      2, 2 (ethylene di amino) di-1-
                                 butanol di hydro chloride.
Physical and chemical properties 48
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Appearance                                   :       White crystalline powder
Melting point                                :        199 - 2040C
Solubility                                      :    Soluble in water and alcohol and slightly soluble 
      in chloroform
Dose                                              :     15mg/kg body weight
Mechanism of action 
          Ethambutol diffuses in to actively growing mycobacterium tuberculosis such as
tubercle bacilli. Ethambutol appears to inhibit the synthesis of one or more metabolites 49,
thus causing impairment of cell metabolism, arrest multiplication and cause cell death.
PHARMACOKINETICS
Absorption 50
          Absorption is rapid. Food doesn’t show any effect of absorption, following a
dosage of 25mg/kg body weight, a peak serum concentration of 4to 5mg/L is achieved
with in 2-4 hrs after administration.
Distribution
         Ethambutol is distributed to tissues and body fluids except cerebrospinal fluid.
Ethambutol  does  not  penetrate  intact  meninges,  but  10  to  50%  may  penetrate  the
meninges of patients with TB meningitis. About 30% of drug binds to plasma proteins.
Time taken to attain peak plasma concentration is about 2to 4 hours.
                                     Volume of distribution   :    1.6 lit/kg
     Biological Half life           :     3 to 4 hours
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Elimination
          Ethambutol gets eliminated by kidney 50 to 90% of drug is excreted as unchanged
form in urine. And 20 to 22 % get excreted in feaces. 80% of ethambutol is eliminated by
glomerular filtration and tubular secretion.
Drug interactions 
1. Magnesium antacid reduces ethambutol resorption and lowers and delays respectively
Cmax and Tmax.  
2. Ethionamide and isoniazid in combination increases ethambutol occular toxicity
Adverse drug reactions 
             1. Aplastic anaemia51, occular toxicity
2. Hallucination, loss of apetite
                                            3. Dark urine, yellowing of skin
   Use            :  Used in combination with anti-tubercular drug for
                        the treatment of tuberculosis.
  Storage      : Stored at 15 - 300C in well closed container.
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MATERIALS 
6. MATERIALS AND INSTRUMENTS
6.1 MATERIALS 
Four  fixed  dose  formulations  manufactured  by  licensed  firms  and  different
combinations of anti-tuberculosis drugs containing rifampicin, isoniazid, ethambutol and
pyrazinamide were purchased from chemist shops which are packed in blister and strip
packaging. The products are purchased in sufficient quantity to fulfill the study storage
plan.
Storage of samples:
Three blister (F1, F2, F3) and one strip (F4) packaged FDC products of equal
strength  were  procured  and  were  investigated  without  cutting  to  avoid  damage  to
packaging material or channel formation during cutting. One strip/blister of each type
was kept in every storage condition and a minimum of three tablets were taken from the
same  package  were  analyzed.  One  set  of  each  package  was  stored  under  ambient
conditions at 250C, freezer at 40 C and stability chamber at 400C with 75% RH.
Table-2 Formulation code for different type of packages
Type of
package
Formulation code Dose
Blister F1 Rifampicin-150mg,Isoniazid-75mg,
Pyrazinamide-400mg Ethambutol- 275mg.
Blister F2 Rifampicin-150mg,Isoniazid-75mg,
Pyrazinamide-400mg Ethambutol- 275mg
Blister F3 Rifampicin-150mg,Isoniazid-75mg,
Pyrazinamide-400mg Ethambutol-275mg
Strip F4 Rifampicin-150mg,Isoniazid-75mg,
Pyrazinamide-400mg Ethambutol- 275mg
33
Equipment: 
Table 3- The following equipments were used in the study
Instrument Manufacturer
Hardness tester Erweka GmbH Heusenstamm, Germany
Dissolution tester Electro lab, Mumbai, India
UV-VIS spectrophotometer Beckman 640i, Fullerton, CA, USA
Stability chamber WTC Binder , Tuttlingen, Germany
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METHODOLOGY
7. METHODOLOGY
   7.1  Physical  evaluation  parameters:  Marketed  tablets  containing  fixed  dose
combinations of rifampicin, isoniazid, pyrazinamide and ethambutol were evaluated for
physical parameters like hardness, weight variation and drug content.
Hardness test: For each formulation, the hardness of 3 tablets was determined by using
Monsanto hardness tester and standard deviations were calculated.
 Weight variation test:  To study weight variation, of tablet of each formulation were
weighed using an electronic balance and the test was performed according to the USP
official limits of percentage deviation of tablet are presented in the table 4.
%Maximum positive deviation= (WH-A/A) ×100
%Minimum negative deviation= (A-WL/A) ×100
             Where,    
                                     WH= Highest weight in mg
                       WL= Lowest weight in mg
                        A= Average weight of tablet in mg
Table 4: USP official limits of weight variation test
Drug content uniformity
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Average weight of
tablet(mg)
Maximum percentage
difference allowed
130 or less 10
130-324 7.5
More than 324 5
Standard preparation
          An accurately weighed amount of pure rifampicin (100 mg) taken and transferred
into 100 ml volumetric flask. It was dissolved and made up to volume with pH 1.2 and
absorbance was measured at 476 nm.
Sample preparation
          Tablets were weighed individually then placed in a mortar and powdered with a
pestle. An amount of powdered rifampicin (100 mg) was extracted in 0.1 N Hcl. The
absorbance was measured at 476 nm after suitable dilution.
Calculation
          The amount of rifampicin present in tablet can be calculated using the formula
At/AsXSw/100X100/StXAv
                    Where,
At= Absorbance of sample preparation
As= Absorbance of standard preparation
Sw= Weight of rifampicin working standard
St = Weight of rifampicin tablet (mg)
Av = Average weight of tablet (mg)
7.2 Construction of standard curve for rifampicin:
          Rifampicin is estimated spectrophotometrically at 475 nm.
Preparation of 0.1 N HCl 52
          Dissolve 8.5 ml of concentrated HCl in 1000 ml of distilled water.
Preparation of standard drug solution
Stock solution
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        100 mg of was dissolved in 100 ml of 0.1 N HCl, to get a solution of 1000 µg/ml
concentration.
Standard solution 
          10 ml of stock solution was made to 100 ml with 0.1 N HCl thus giving a
concentration of 100 µg/ml. Aliquot of standard drug solution ranging from 0.5 ml, 1 ml,
1.5 ml, 2 ml and 2.5 ml were transferred into 10 ml volumetric flask and were diluted up
to  the  mark  with  0.1  N HCl.  Thus  the  final  concentration  ranges  from 5-25  µg/ml.
Absorbance of each solution was measured at 475 nm against 0.1 N HCl as a blank.  A
plot of concentrations of drug versus absorbance was plotted.
7.3In- vitro Dissolution study
Dissolution studies were performed for the fixed dose combination tablets  by  using
dissolution medium of 0.1N (HCl), 900 ml in USP dissolution apparatus II at 50 rpm and
370 ± 0.50C Tablets were weighed individually and subjected to dissolution testing. 5ml
sample was withdrawn at regular intervals ( 15, 30, 45 and 60 minutes ) and diluted to
1ml  with  dissolution  medium and  drug  content  was  determined  by  using  Uv-visible
spectrophotometer  at  475nm.53An  equal  volume  of  fresh  medium  was  replaced  to
maintain the dissolution medium and the percentage degradation was calculated by using
the given formulae 5
PercentageDegradation=
Initial concentrationFinal concentration
Initial concentration
×100
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RESULTS
8. RESULTS
8.1  Physical  evaluation  parameters:  Marketed  tablets  containing  fixed  dose
combinations of rifampicin, isoniazid, pyrazinamide and ethambutol were evaluated for
physical parameters like hardness, weight variation and drug content.
Hardness:
Hardness was performed for the marketed fixed dose combination tablets and the results 
are given in the following table. All tablets passed hardness test and all the tablets was 
found to be within pharmacoepial limits.
At 40c:
The value of F1 ranges between 4.6 ± 0.39 to 3.8 ± 0.61(kg/cm2) (P < 0.001), value of F2
ranges from 4.5 ± 0.43 to 3.9 ± 0.25 (kg/cm2) (P < 0.01), value of F3 ranges from 4.5 ±
0.25 to   4.1 ± 0.32(kg/cm2) (P < 0.001) and the value of F4 ranges from 4.6 ± 0.33 to 4.2
± 0.26 (kg/cm2) (P < 0.001).
Table.4- Hardness of tablets stored at 40C
Formulation
code
Initial
(kg/cm2)
After 15
days(kg/cm2)
After 30
days(kg/cm2)
After 45
days(kg/cm2)
After 60
days(kg/cm2)
F1 4.6 ± 0.39 4.6 ± 0.54 4.4 ± 0.36 4.1 ± 0.56 3.8 ± 0.61
F2 4.5 ± 0.43 4.5 ± 0.39 4.3 ± 0.42 4.1 ± 0.37 3.9 ± 0.25
F3 4.5 ± 0.25 4.5 ± 0.63 4.4 ± 0.27 4.3 ± 0.54 4.1 ± 0.32
F4 4.6 ± 0.33 4.6 ± 0.31 4.5 ± 0.37 4.4 ± 0.81 4.2 ± 0.26
At 300C:
The value of F1 ranges between 4.6 ± 0.39 to 3.7 ± 0.29(kg/cm2) (P < 0.001), value of F2
ranges from 4.5 ± 0.53 to 3.8 ± 0.36(kg/cm2) (P < 0.01), value of F3 ranges from 4.5 ±
0.44 to 3.8 ± 0.31(kg/cm2) (P < 0.001), the value of F4 ranges from 4.6 ± 0.36 to 3.9 ±
0.66 (kg/cm2) (P < 0.01).
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Table.5- Hardness of tablets stored at 300C
Formulation
code
Initial
(kg/cm2)
After 15
days(kg/cm2)
After 30
days(kg/cm2)
After 45
days(kg/cm2)
After 60
days(kg/cm2)
F1 4.6 ± 0.62 4.4 ± 0.87 4.1 ± 0.58 3.9 ± 0.39 3.7 ± 0.29
F2 4.5 ± 0.53 4.3 ± 0.48 4.2 ± 0.29 4.1 ± 0.73 3.8 ± 0.36
F3 4.5 ± 0.44 4.4 ± 0.36 4.3 ± 0.77 4.0 ± 0.29 3.8 ± 0.31
F4 4.6 ± 0.36 4.5 ± 0.39 4.2 ± 0.23 4.2 ± 0.37 3.9 ± 0.66
AT 400C:
The value of F1 ranges between 4.6 ± 0.39 to 3.1 ± 0.22(kg/cm2) (P < 0.01), value of F2
ranges from 4.5 ± 0.53 to 3.3 ± 0.39(kg/cm2) (P < 0.001) value of F3 ranges from 4.5 ±
0.44 to 3.4 ± 0.43(kg/cm2), (P < 0.01), the value of F4 ranges from 4.6 ± 0.36 to 3.7 ±
0.64(kg/cm2) (P < 0.01).
Table.6- Hardness of tablets stored at 400C
Formulation
code
Initial
(kg/cm2)
After 15
days(kg/cm2)
After 30
days(kg/cm2)
After 45
days(kg/cm2)
After 60
days(kg/cm2)
F1 4.6 ± 0.23 4.0 ± 0.33 3.7 ± 0.29 3.4 ± 0.65 3.1 ± 0.22
F2 4.5 ± 0.49 4.1 ± 0.57 3.8 ± 0.36 3.6 ± 0.40 3.3 ± 0.39
F3 4.5 ± 0.56 4.2 ± 0.42 3.9 ± 0.49 3.7 ± 0.58 3.4 ± 0.43
F4 4.6 ± 0.72 4.3 ± 0.73 4.1 ± 0.59 3.9 ± 0.39 3.7 ± 0.64
WEIGHT VARIATION:
   Weight variation was performed for the marketed fixed dose combination tablets and
the results are given in the following table. The weight variation of all tablets was found
to be within the pharmacoepial limits of ± 5%.
AT 40C:
The value of F1 ranges between 1230 ± 36.05 to 1243 ± 20.81(mg) (P < 0.001), value of
F2 ranges between 1078 ± 25.65 to 1201 ± 38.18(mg) (P < 0.001), value of F3 ranges
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from 1146 ± 45.09 to 1253 ± 30.50(mg) (P < 0.001), the value of F4 ranges from 1230 ±
36.05 to 1186 ±15.27(mg) (P < 0.001).
Table.7-Weight variation of tablets stored at 40C
Formulation
code
    Initial(mg) After 15 
days(mg)
After 30 
days(mg)
After 45 
days(mg)
After 60 
days(mg)
FI 1230 ± 36.05 1230 ± 36.05 1246 ± 15.27 1246 ± 25.16 1243 ± 20.81
F2 1078 ± 25.65 1130 ± 75.49 1090 ± 26.45 1163 ± 65.06 1201 ± 38.18
F3 1146 ± 45.09 1150 ± 30.00 1150 ± 30.00 1126 ± 94.51 1253 ± 30.50
F4 1230 ± 36.05 1140 ± 90.00 1143 ± 15.27 1193 ± 32.14 1186 ±15.27
At 300C:
The value of F1 ranges between 1230 ± 36.05 to 1275 ± 51.00(mg) (P < 0.01) value of F2
ranges between 1078 ± 25.65 to 1201 ± 38.18 (mg) (P < 0.01) value of F3 ranges from
1146 ± 45.09 to 1241 ± 41.00(mg) (P < 0.001)  the value of F4 ranges from 1230 ± 36.05
to 1148 ± 18.93(mg) (P < 0.01).
Table.8-Weight variation of tablets stored at 300C
Formulation
code
    Initial(mg) After 15 
days(mg)
After 30 
days(mg)
After 45 
days(mg)
After 60 
days(mg)
FI 1230 ± 36.05 1236 ±25.16 1240 ± 36.05 1266 ± 30.55 1275 ± 51.00
F2 1078 ± 25.65 1140 ±55.67 1180 ± 55.67 1146 ± 41.63 1213 ± 35.11
F3 1146 ± 45.09 1193 ±25.16 1240 ± 30.00 1160 ± 26.45 1241 ± 41.00
F4 1230 ± 36.05 1173 ±25.16 1180 ± 26.45 1156 ± 51.31 1148 ± 18.93
AT 400C:
The value of F1 ranges between 1230 ± 36.05 to 1180 ± 18.53 (mg) (P < 0.001) value of
F2 ranges between 1078 ± 25.65 to 1230 ± 26.45(mg) (P < 0.001) value of F3 ranges
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from 1146 ± 45.09 to 1330 ± 39.34(mg) (P < 0.001) the value of F4 ranges from 1230 ±
36.05 to 1220 ± 20.00(mg) (P < 0.001).
Table.9-Weight variation of tablets stored at 400C
Formulation
code
    Initial(mg) After 15 
days(mg)
After 30 
days(mg)
After 45 
days(mg)
After 60 
days(mg)
FI 1230 ± 36.05 1245 ± 15.0 1196 ± 25.16 1181 ± 26.45 1180 ± 18.53
F2 1078 ± 25.65 1178 ± 20.20 1230 ± 20.00 1251 ± 17.51 1230 ± 26.45
F3 1146 ± 45.09 1243 ± 15.27 1093 ± 40.41 1146 ± 25.09 1330 ± 39.34
F4 1230 ± 36.05 1143 ± 25.16 1153 ± 45.09 1203 ± 25.16 1220 ± 20.00
DRUG CONTENT:
Drug content  was performed for the marketed fixed dose combination tablets and the
results are given in the following table. The drug content of all the tablets was found to be
within the range of (80-110) %.
AT 40C:
The value of F1 ranges between 118 ± 0.375 to 96.3 ± 0.132(%) (P < 0.001) value of F2
ranges between 103 ± 0.195 to 97.5 ± 0.242(%) (P < 0.001) value of F3 ranges from 110
± 0.069 to 96.9 ± 0.139(%) (P < 0.001) the value of F4 ranges from 107 ± 0.129 to 91.2 ±
0.299(%)  (P < 0.001).
Table.10- Drug content of tablets stored at 40C
Formulation
code
Initial (%) After 15 days
(%)
After 30 days
(%)
After
45days (%)
After 60
days (%)
FI 118 ± 0.375 110.4 ± 0.286 109.7 ± 0.692 102.4±0.236 96.3 ± 0.132
F2 103 ±
0.195
100.7 ± 0.199 99.0 ± 0.329 98.1 ± 0.329 97.5 ± 0.242
F3 110 ± 0.069 103.2 ± 0.174 98.6 ± 0.192 96.9 ± 0.232 96.9 ± 0.139
F4 107 ±
0.129
101.9 ± 0.261 97.4 ± 0.229 93.8 ± 0.189 91.2 ± 0.299
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At 300C
The value of F1 ranges between 118 ± 0.375 to 91.2 ± 0.329(%) (P < 0.001) value of F2
ranges between 103 ± 0.242 to 90.8 ± 0.234(%) (P < 0.01) value of F3 ranges from 110 ±
0.329 to 91.7 ± 0.256 (%) (P < 0.001) the value of F4 ranges from 107 ± 0.295 to 90.6 ±
0.136 (%)  (P < 0.01).
Table.11- Drug content of tablets stored at 300C
Formulation
code
Initial (%) After 15 days
(%)
After 30
days (%)
After 45
days (%)
After 60
days (%)
F1 118 ± 0.141 105 ± 0.163 99.3 ± 0.124 95.4 ± 0.149 91.2 ± 0.329
F2 103 ± 0.242 99.6 ± 0.121 96.7 ± 0.392 93.2 ± 0.126 90.8 ± 0.234
F3 110 ± 0.329 100.8 ±
0.321
94.8 ± 0.369 94.8 ± 0.023 91.7 ± 0.256
F4 107 ± 0.295 98.9 ± 0.331 92.7 ± 0.135 92.7 ± 0.235 90.6 ± 0.136
AT 400C
The value of F1 ranges between 118 ± 0.375 to 87.6 ± 0.026(%) (P < 0.001) value of F2
ranges between 103 ± 0.234 to 85.4 ± 0.321 (%) (P < 0.001) value of F3 ranges from 110
± 0.322 to 88.3 ± 0.125(%) (P < 0.01) the value of F4 ranges from 107 ± 0.069 to 83.7 ±
0.312 (P < 0.01).
Formulation
code
Initial (%) After 15
days (%)
After 30
days (%)
After 45
days (%)
After 60 days
(%)
F1 118 ± 0.141 101 ± 0.163 97.8 ± 0.124 91.2 ± 0.062 87.6 ± 0.026
F2 103 ± 0.234 97 ± 0.223 94.1 ± 0.234 89.9 ± 0.139 85.4 ± 0.321
F3 110 ± 0.322 104.3± 0.121 98.8 ± 0.369 92.7 ± 0.392 88.3 ± 0.125
F4 107 ± 0.069 100.4 ±0.095 96.5 ± 0.251 80.3 ± 0.523 83.7 ± 0.312
Table.12- Drug content of tablets stored at 400 C
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IN-VITRO DRUG RELEASE FOR MARKETED FIXED DOSE COMBINATION 
TABLETS
Determination of standard curve for rifampicin in pH 0.1N HCL medium
Standard  curve  of  rifampicin  was  determined  by  using  UV-  spectrophotometer  at
476nm.Graph was plotted by taking absorbance (nm) on X axis versus  concentration
(µg/ml) on Y-axis the results were shown in the table
                Table.13 Standard curve of rifampicin in pH 0.1N HCL medium
Concentration (µg/ml) Absorbance ( nm)
5 0.079
10 0.14
20 0.3
30 0.44
40 0.58
50 0.69
Standard curve of rifampicin in 0.1N HCL
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8.2 INVITRO DRUG RELEASE PROFILE BEFORE STORAGE
The stability of rifampicin was ascertained from the % release of drug at 60 minutes. As
rifampicin was absorbed maximum within an hour from acidic Environment of stomach
so the release is confined to 60 minutes.
Table.14 Invitro drug release profile for formulation F1 before storage
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Time(min)
Absorbance
(nm)
Concentratio
n(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug
Release
15 0.052 3.77 34.00
22.67 ± 0.012
30 0.08 5.72 51.49
34.33 ± 0.009
45 0.115 8.27 74.50
49.67 ± 0.816
60 0.148 10.62 95.64
63.76 ± 1.724
**P<0.001
Time(min)
Absorbance
(nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.058 4.21 37.95 25.33 ± 0.062
30 0.084 6.05 54.48 36.32 ± 0.011
45 0.117 8.37 75.37 50.25 ± 0.016
60 0.149 10.71 96.40
64.27 ± 0.571
**P<0.01
Table.16 Invitro drug release profile for formulation F2 before storage
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative %Drug
Release
15 0.064 4.58 41.29 27.53 ± 0.429
30 0.090 6.43 57.88 38.59 ± 0.436
45 0.119 8.57 77.19 51.46 ± 0.149
60 0.15 10.89 98.01 65.34 ± 0.277
**P<0.01
Table.17 Invitro drug release profile for formulation F4 before storage
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.07 5.01 45.13 30.09 ± 0.530
30 0.096 6.92 62.31 41.84 ± 0.072
45 0.125 8.96 80.65 53.77 ± 0.294
60 0.16 11.46 103.2 68.8 ± 0.140
**P<0.01
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8.3 IN VITRO DRUG RELEASE PROFILE AT 40C
Table.18 In- vitro drug release profile for formulation F1 after 15 days at 40C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.04 3.50 31.56 21.04 ± 0.394
30 0.075 5.42 48.79 32.53 ± 0.135
45 0.12 8.61 77.56 51.71 ± 0.179
60 0.145 10.41 93.76 62.51 ± 0.355
**P<0.001
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Table.19 In vitro drug release profile for formulation F2 after 15 days at 40C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.053 3.82 34.41 22.94 ± 0.140
30 0.079 5.65 50.92 33.95 ± 0.392
45 0.112 8.06 72.61 48.41 ± 0.364
60
 
0.147 10.5 94.56 63.04 ± 0.475
**P<0.01
Table.20 In vitro drug release profile for formulation F3 after 15 days at 40C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.06 4.33 39.02 26.06 ± 0.129
30 0.08 6.2 55.86 37.24 ± 0.281
45 0.118 8.49 76.44 50.96 ± 0.156
60 0.149 10.7 96.34 64.23 ± 0.387
**P<0.01
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Table.21 In vitro drug release profile for formulation F4 after 15 days at 40C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.065 4.66 42.01 28.01 ± 0.125
30 0.094 6.76 60.84 40.56 ± 0.128
45 0.119 8.53 76.84 51.23 ± 0.162
60 0.131 11.38 102.42 68.28 ± 0.152
**P<0.01
The percentage drug release of rifampicin in 0.1N HCL before storage was found to be
68 % and after storage for 15 days at 40C there was no change in the percentage of drug
release this indicates that there was no degradation for after 15 days.
                                                               
0 10 20 30 40 50 60 70
0
20
40
60
80
Comparative study of marketed products after 15 days 
f1
f2
f3
f4
Time (min)C
u
m
u
la
tiv
e 
%
 
 
dr
u
g 
re
le
as
e
Fig.3
48
INVITRO DRUG RELEASE PROFILE AFTER 30 DAYS AT 40C
Table.22 In vitro drug release profile for formulation F1 after 30 days at 40C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.046 3.34 30.1 20.07 ± 0.212
30 0.075 5.18 46.02 31.08 ± 0.240
45 0.117 8.42 75.85 50.57 ± 0.183
60 0.144 10.34 93.06 62.04 ± 0.201
**P<0.01
Table.23 In vitro drug release profile for formulation F2 after 30 days at 40C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.049 3.5 31.54 21.03 ± 0.181
30 0.074 5.34 48.09 32.06 ± 0.103
45 0.119 8.5 76.53 51.02 ± 0.201
60 0.145 10.42 93.78 62.52 ± 0.278
**P<0.01
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Table.24 In vitro drug release profile for formulation F3 after 30 days at 40C
Time(min) Absorbance 
(nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug 
Release
15 0.017 4.08 36.76 24.51 ± 0.013
30 0.081 5.84 52.56 35.04 ± 0.008
45 0.118 8.49 76.42 50.95 ± 0.140
60 0.148 10.58 95.22 63.48 ± 0.026
**P<0.01
Table.25 In vitro drug release profile for formulation F4 after 30 days at 40C
Time(min) Absorbanc
e (nm)
Concentration(
µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.065 4.65 41.89 27.93 ± 0.411
30 0.091 6.53 58.83 39.22 ± 0.132
45 0.116 8.34 75.12 50.08 ± 0.067
60 0.157 11.23 101.07 67.38 ± 0.430
**P<0.001
50
 The percentage drug release of rifampicin after storage for 15 days at 40C was found to
be 68% and after 30 days the drug release was decreased to 63% due to degradation.
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INVITRO DRUG RELEASE PROFILE AFTER 45 DAYS AT 40C
Table.26 In vitro drug release profile for formulation F1 after 45 days at 40C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.051 3.7 33.37 22.25 ± 0.291
30 0.074 5.31 47.79 31.86 ± 0.121
45 0.12 8.59 77.38 51.59 ± 0.045
60 0.143 10.28 92.52 61.68 ± 0.406
**P<0.01
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Table.27 In vitro drug release profile for formulation F1 after 45 days at 40C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.054 3.86 34.77 23.18 ± 0.196
30 0.076 5.45 49.11 32.74 ± 0.134
45 0.121 8.71 78.45 52.30 ± 0.121
60 0.144 10.31 92.79 61.86 ± 0.172
**P<0.01
.
Table.28 In vitro drug release profile for formulation F3 after 45 days at 40C
Time(min) Absorban
ce (nm)
Concentratio
n(µg/ml)
Amount Of
drug
release(mg)
Cumulative %Drug
Release
15 0.056 4.03 37.27 24.18 ± 0.111
30 0.077 5.52 49.71 33.14 ± 0.286
45 0.124 8.87 79.90 53.27 ± 0.244
60 0.146 10.49 94.49 62.94 ±0.143
52
*** P< 0.001
Table.29 In vitro drug release profile for formulation F3 after 45 days at 40C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.062 4.48 43.38 26.92 ± 0.081
30 0.09 6.44 58.02 38.68 ± 0.092
45 0.114 8.21 73.89 49.32 ± 0.084
60 0.165 11.18 100.62 67.08 ± 0.054
**P<0.01
The percentage drug release of rifampicin after storage for 45 days at 40C was reduced
further due to the formation of degradation.
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Fig-5
INVITRO DRUG RELEASE PROFILE AFTER 60 DAYS AT 40C
Table.30 In vitro drug release profile for formulation F1 after 60 days at 40C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.045 3.26 29.37 19.58 ± 0.115
30 0.082 5.87 52.90 30.27 ±0.0.121
45 0.115 8.25 74.31 49.54 ±0.0.216
60 0.142 10.17 91.53 61.02 ± 0.0.134
**P<0.01
Table.31 In vitro drug release profile for formulation F2 after 60 days at 40C
Time(min) Absorbanc
e (nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.049 3.55 31.95 21.34 ±0.126
30 0.071 5.12 46.15 30.77 ± 0.315
45 0.118 8.43 75.91 50.64 ± 0.268
60 0.143 10.22 91.98 61.32 ± 0.427
54
**P<0.001
Table.32 In vitro drug release profile for formulation F3 after 60 days at 40C
Time(min) Absorbanc
e (nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.055 3.93 35.37 23.58 ± 0.109
30 0.088 6.30 56.74 37.83 ± 0.542
45 0.12 8.62 77.44 51.63 ± 0.136
60 0.145 10.36 93.24 62.16 ± 0.251
**P<0.01
Table.33 In vitro drug release profile for formulation F4 after 60 days at 40C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.063 4.56 41.1 27.40 ± 0.109
30 0.091 6.52 58.74 39.16 ± 0.458
45 0.117 8.39 75.51 50.34 ± 0.136
60 0.155 11.09 99.89 66.54 ± 0.251
**P<0.001
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When compared to F1,  F2,  F3 andF4 formulations stored at  40c the percentage drug
release of rifampicin was found to be reduced more after 60 days and in F4 formulation
less amount of rifampicin get released due to less degradation because F4 formulation is
strip pack formulation. 
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8.4 IN VITRO DRUG RELEASE PROFILE 30° C
  Table.34 In vitro drug release profile for formulation F1 after 15 days at 300C
Time(min) Absorbance 
(nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.046 3.31 29.80 19.87 ± 0.213
30 0.072 5.15 46.41 30.94 ± 0.174
45 0.115 8.28 74.56 49.71 ± 0.571
60 0.144 10.32 92.88 61.92 ± 0.482
56
**P<0.01
  
Table.35 In vitro drug release profile for formulation F2 after 15 days at 300C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.049 3.5 31.5 21.04 ± 1.07
30 0.073 5.28 47.99 31.73 ± 0.954
45 0.117 8.28 75.48 50.32 ± 0.472
60 0.145 10.42 93.78 62.52 ± 0.218
**P<0.01
Table.36 In vitro drug release profile for formulation F3 after 15 days at 300C
Time(min) Absorbanc
e (nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15
0.055 3.97 35.77 23.85 ± 0.189
30 0.081 5.79 52.11 34.74 ± 0.361
57
45 0.115 8.28 74.5 49.68 ± 0.437
60 0.147 10.52 94.68 63.12 ± 0.207
**P<0.01
Table.37 In vitro drug release profile for formulation F4 after 15 days at 300C
Time(min) Absorbanc
e (nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.064 4.59 41.31 27.54 ± 0.115
30 0.092 6.58 59.29 39.53 ± 0.089
45 0.116 8.34 98.55 50.05 ± 0.673
60 0.157 11.23 101.07 67.38 ± 0.954
**P<0.01
The percentage drug release of rifampicin after storage for 15 days at 40C is found to be 
68% and the percentage drug release after storage for 15 days at 300C is found to be 67%.
Fig-7
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Table.38 In vitro drug release profile for formulation F1 after 45 days at 300C
Time(min) Absorbanc
e (nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.039 2.82 25.41 16.94 ± 0.231
30 0.066 4.77 42.97 28.65 ± 0.135
45 0.111 7.99 71.95 47.97 ± 0.189
60 0.14 10.06 90.54 60.36 ± 0.159
**P<0.01
Table.39 In vitro drug release profile for formulation F2 after 45 days at 300C
59
Time(min) Absorbanc
e (nm)
Concentratio
n(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.04 3.08 27.78 18.52 ± 0.243
30 0.067 4.96 44.68 29.79 ± 0.296
45 0.113 8.07 72.70 48.47 ± 1.59
60 0.142 10.13 91.17 60.78 ± 0.087
**P<0.001
Table.40 In vitro drug release profile for formulation F3 after 45 days at 300C
Time(min) Absorbanc
e (nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.045 3.22 21.04 19.36 ± 0.026
30 0.071 5.12 46.11 30.74 ± 0.061
45 0.119 8.20 73.84 49.23 ± 0.765
60 0.146 10.31 92.79 61.86 ± 1.609
**P<0.01
Table.41   In vitro drug release profile for formulation F4 after 45 days at 300C
60
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.065 4.611 41.5 27.67 ± 2.18
30 0.088 6.35 57.18 38.12 ±1.609
45 0.118 8.46 76.2 50.8 ± 0.066
60 0.154 11 99 66.1 ± 1.327
**P<0.001
The percentage drug release of rifampicin after 30 days was found to be 66%
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Table.42 In vitro drug release profile for formulation F1 after 45 days at 300C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
61
15 0.051 3.7 33.37 22.25 ± 0.273
30 0.074 5.31 47.79 31.86 ± 0.791
45 0.12 8.59 77.38 51.59 ± 0.198
60 0.143 10.28 92.52 61.68 ± 0.111
**P<0.01
Table.43 In vitro drug release profile for formulation F2 after 15 days at 300C
Time(min) Absorbanc
e (nm)
Concentratio
n(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.054 3.86 34.77 23.18 ± 0.176
30 0.076 5.45 49.11 32.74 ± 0.329
45 0.121 8.71 78.45 52.30 ± 0.980
60 0.144 10.31 92.79 61.86 ± 0.876
**P<0.001
.
Table.44 In vitro drug release profile for formulation F3 after 45 days at 300C
62
Time(min) Absorbanc
e (nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.056 4.03 37.27 24.18 ± 0.299
30 0.077 5.52 49.71 33.14 ± 0.351
45 0.124 8.87 79.90 53.27 ± 1.125
60 0.146 10.49 94.49 62.94 ± 1.596
**P<0.01
Table.45 In vitro drug release profile for formulation F4 after 45 days at 300C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.062 4.48 43.38 26.92 ±0.242
30 0.09 6.44 58.02 38.68 ± 1.29
45 0.114 8.21 73.89 49.26 ± 1.53
60 0.165 11.18 100.62 67.08 ± 2.98
**P<0.01
63
When compared to percentage drug release for 30 days and 45 days there was no change 
in the percentage of drug release.
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Table.46 In vitro drug release profile for formulation F1 after 60 days at 300C
Time(min) Absorbanc
e (nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.046 3.32 29.91 19.94 ± 0.242
30 0.066 4.72 42.48 28.32 ± 2.98
45 0.11 7.86 70.77 47.18 ± 0.257
60 0.139 9.91 89.19 59.46 ± 1.29
**P<0.001
64
Table.47 In vitro drug release profile for formulation F2 after 60 days at 300C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.044 3.15 28.38 18.92 ± 0.181
30 0.064 4.62 41.59 27.73 ± 0.255
45 0.108 7.78 70.06 46.79 ± 0.462
60 0.138 9.86 88.74 59.16 ± 0.921
**P<0.01
Table.48 In vitro drug release profile for formulation F3 after 60 days at 300C
Time(min) Absorbanc
e (nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.047 3.40 30.61 20.41 ± 0.293
30 0.068 4.89 44.05 29.37 ± 0.114
45 0.113 8.10 72.93 48.62 ± 0.525
60 0.140 10.01 90.09 60.06 ± 0.139
**P<0.01
Table.49 In vitro drug release profile for formulation F4 after 60 days at 300C
65
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.057 4.08 36.73 24.49 ± 0.035
30 0.078 5.62 50.62 33.76 ± 0.352
45 0.121 8.71 78.45 52.30 ± 0.305
60 0.146 10.46 94.14 62.76 ± 0.237
**P<0.001
The percentage of drug release of rifampicin after 60 days was found to be 62% due to
more amount drug get degraded at 300C.When compared to 40C and 300C the degradation
was found to be more in 300C.
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8.5 IN VITRO DRUG RELEASE PROFILE AT 400C
Table.50 In vitro drug release profile for formulation F1 after 15 days at 400C
Time(min) Absorbanc
e (nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.042 3.04 27.43 18.29 ± 0.092
30 0.070 5.04 45.36 30.24 ± 0.304
45 0.114 8.19 73.77 49.18 ± 0.275
60 0.141 10.13 91.17 60.78 ± 0.076
**P<0.001
Table.51 In vitro drug release profile for formulation F2 after 15 days at 400C
Time(min) Absorbance 
(nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.040 2.91 26.25 17.5 ± 0.038
30 0.064 4.93 44.41 29.61 ± 0.045
45 0.112 8 72.04 48.03 ± 0.083
60 0.141 10.11 90.99 60.66 ± 0.070
**P<0.01
67
Table.52 In vitro drug release profile for formulation F3 after 15 days at 400C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.034 2.46 31.15 20.77 ± 0.048
30 0.073 5.28 47.53 31.69 ± 0.039
45 0.116 8.34 75.09 50.06 ± 0.051
60 0.144 10.34 93.06 62.04 ± 0.042
**P<0.01
Table.53 In vitro drug release profile for formulation F4 after 15 days at 400C
Time(min) Absorbanc
e (nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.066 4.78 43.02 28.68 ± 0.048
30 0.092 6.62 59.59 39.73 ± 0.348
45 0.121 8.71 78.39 52.26 ± 0.266
60 0.154 11 99 66.04 ± 0.362
**P<0.01
68
The percentage drug release of rifampicin after 15 days at 400C is found to be 66%.
0 10 20 30 40 50 60 70
0
10
20
30
40
50
60
70
Comparative study of marketed products before storage after   days    
f1
f2
f3
f4
Time ( min)
Cu
m
u
la
tiv
e 
%
 
Dr
u
g 
re
le
as
e
Fig-11
Table.54 In vitro drug release profile for formulation F1 after 30 days at 400C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.040 2.88 25.96 17.39 ± 0.908
30 0.067 4.79 43.17 28.78 ± 0.168
45 0.111 7.96 71.76 47.84 ± 0.754
60 0.139 9.94 89.46 59.64 ± 0.958
**P<0.001
69
Table.55 In vitro drug release profile for formulation F2 after 30 days at 400C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.043 3.09 27.82 18.55 ± 0.121
30 0.069 4.94 44.46 19.64 ± 1.154
45 0.112 8.03 72.34 48.23 ± 0.329
60 0.14 9.98 89.82 59.88 ± 0.258
**P<0.01
Table.56 In vitro drug release profile for formulation F3 after 30 days at 400C
Time(min) Absorbanc
e (nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.04 3.2 28.83 19.22 ± 0.707
30 0.071 5.13 46.18 30.79 ± 0.383
45 0.115 8.28 74.56 49.71 ± 1.603
60 0.141 10.09 90.81 60.54 ± 0.923
**P<0.001
Table.57 In vitro drug release profile for formulation F3 after 30 days at 400C
70
Time(min) Absorbanc
e (nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15 0.064 4.58 41.25 27.5 ± 0.837
30 0.088 6.35 57.22 38.15 ± 1.39
45 0.12 8.61 77.5 51.67 ± 0.083
60 0.153 10.94 98.46 65.64 ± 0.057
**P<0.001
The percentage drug release of rifampicin after 30 days was found to be 65%
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Table.58 In vitro drug release profile for formulation F1 after 45 days at 400C
Time(min) Absorbanc
e (nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.044 3.21 28.89 19.26 ±0.547
30 0.067 4.81 43.30 88.87 ±0.321
45 0.11 7.911 71.20 47.42 ±0.145
60 0.138 9.89 89.01 59.34 ± 0.732
**P<0.01
Table.59 In vitro drug release profile for formulation F2 after 45 days at 400C
Time(min) Absorbanc
e (nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.042 3.06 77.54 18.36 ± 0.257
30 0.063 4.57 41.14 27.43 ± 0.236
45 0.107 7.71 69.45 46.30 ± 0.017
60 0.137 9.85 88.65 59.11 ± 0.997
**P<0.01
72
Table.60 In vitro drug release profile for formulation F3 after 45 days at 400C
Time(min) Absorbanc
e (nm)
Concentration
(µg/ml)
Amount Of 
Drug 
Release(mg)
Cumulative 
%Drug Release
15
0.045 3.25 29.23 19.52 ± 0.021
30 0.071 5.14 46.35 30.89 ± 0.063
45 0.074 5.30 74.76 49.82 ± 0.034
60 0.14 10.02 90.18 60.12 ± 0.134
**P<0.01
Table.61 In vitro drug release profile for formulation F4 after 45 days at 400C
Time(min) Absorbanc
e (nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.059 4.28 38.55 25.70 ± 0.048
30 0.084 6.03 54.27 36.18 ± 0.011
45 0.113 8.11 72.99 48.66 ± 0.031
60 0.149 10.69 96.21 64.14±0.048
**P<0.002
The  percentage  degradation  of  rifampicin  was  found  to  be  64% and  drug  release  is
reduced more due to degradation of rifampicin is more after 45 days.
73
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The  percentage  degradation  of  rifampicin  was  found  to  be  64% and  drug  release  is
reduced more due to degradation of rifampicin is more after 45 days.
Table.62 In vitro drug release profile for formulation F1 after 60 days at 400C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.022 1.63 14.73 9.82 ± 0.237
30 0.046 3.32 29.91 19.94 ± 0.215
45 0.064 4.60 41.43 27.62 ± 0.228
60 0.085 6.13 55.2 36.89 ± 0.179
**P<0.01
74
Table.63 In vitro drug release profile for formulation F2 after 60 days at 400C
Time(min) Absorbanc
e (nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug Release
15 0.024 1.77 16.0 10.67 ± 0.156
30 0.048 3.45 31.09 20.73 ± 0.024
45 0.068 4.91 44.20 29.47 ± 0.023
60 0.094 6.73 60.06 40.46 ± 0.051
**P<0.01
Table.64 In vitro drug release profile for formulation F3 after 60 days at 400C
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of
Drug
Release(mg)
Cumulative
%Drug
Release
15 0.042 3.0 27.06 18.04 ± 0.019
30 0.057 4.10 36.94 24.73 ± 0.026
45 0.076 5.46 49.21 32.81 ± 0.061
60 0.131 9.4 84.6 56.42 ± 0.110
**P<0.01
Table.65 In vitro drug release profile for formulation F4 after 60 days at 400C
75
Time(min) Absorbance
(nm)
Concentration
(µg/ml)
Amount Of Drug
Release(mg)
Cumulative
%Drug
Release
15 0.028 2.07 18.69 12.46 ± 0.271
30 0.057 4.09 36.88 24.59 ± 0.233
45 0.074 5.29 47.69 31.75 ± 0.030
60 0.10 7.43 66.9 44.69 ± 0.165
**P<0.01
When compared to 15,30,45 and 60 days drug release at 60 days was found to be less
(44%)  due  to  more  amount  of  rifampicin  get  degraded  due  to  gain  in  moisture  by
ethambutol .
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Table. 66 Comparative degradation of F1, F2, F3 and F4 formulations after 15, 30, 45
and 60 days at 40C
76
Formulation
code
Degradation
after 15 days (
%)
Degradation after
30 days ( %)
Degradation after
45 days ( %)
Degradation
after 60 days
(%)
F1 1.9 ± 0.165 2.6 ± 0.138 3.20 ± 0.283 4.23 ± 0.237
F2 1.96 ± 0.239 2.70 ± 0.319 3.73 ± 0.127 4.57 ± 0.521
F3 1.0 ± 0.168 2.12 ± 0.148 2.96 ± 0.693 4.16 ± 0.025
F4 1.69 ± 0.265 2.0 ± 0.293 2.44 ± 0.181 3.22 ± 0.179
**P<0.01
                                                                    Fig-15
                                                                     Fig-15
Table.67 Comparative degradation of F1, F2, F3 and F4 formulations after 15, 30, 45 and
60 days at 300
77
Formulation
code
Degradation
after 15 days
( %)
Degradation
after 30 days
( %)
Degradation
after 45 days
( %)
Degradation
after 60 days
(%)
F1 2.59 ± 0.261 5.27 ± 0.273 5.55 ± 0.069 6.68 ± 0.133
F2 2.70 ± 0.163 5.41 ± 0.076 6.53 ± 0.257 7.93 ± 0.192
F3 2.6 ± 0.242 4.62 ± 0.275 6.38 ± 0.174 7.40 ± 0.181
F4 2.27 ± 0.816 4.01 ± 0.525 4.97 ± 0.195 6.10 ± 0.056
**P<0.01
                                                                    Fig-16
Table.68 Comparative degradation of F1, F2, F3 and F4 formulations after 15, 30, 
45 and 60 days at 400C
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Formulation
code
Degradation
after 15 days
(%)
Degradation
after 30 days
( %)
Degradation
after 45 days
( %)
Degradation
after 60 days
(%)
F1 11.6 ± 0.024 20 ± 0.154 39 ± 0.184 37.2 ± 0.179
F2 10.8 ± 0.312 16 ± 0.142 32 ± 0.199 38 ± 0.352
F3 8.8 ± 0.242 15 ± 0.359 33.85 ± 0.274 39 ± 0.251
F4 7.4 ± 0.139 13.3 ± 0.241 29 ± 0.349 34.2 ± 0.187
**P<0.01
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DISCUSSION
RESULTS AND DISCUSSION
By  comparing  all  four  F1,  F2,  F3  and  F4  formulations  stored  at  different
temperatures like 40C, 300C and 400C with 75%RH. Formulations when stored at 40C
were  found  to  having  the  hardness  with  in  prescribed  limits.  Among  the  four
formulations, formulation F4 is found to be within the range of 4.2 to 4.6 and hence F4
formulation may be considered as the best formulation.
The percentage weight variation of all formulation was found to be within the
pharmacoepial limits. When compared to different temperatures for formulations stored
at  40C  there  was  very  less  fall  in  drug  content  i.e.  91.2%  which  shows  that  the
degradation of drug is very low at 40C when compared to other temperatures
In- vitro stability studies:
Among all the four packaged formulations degradation of rifampicin was found to
be more in blister packages when compared to strip packages because blister packaged
tablets showed discoloration and bleeding inside package due to allowing the moisture to
ingress and resulted in higher degradation which was further supported by the previous
study.11 The another reason for degradation of rifampicin within formulation is due to the
formation hydrazine ( HYD ) which is the main degradation product whenever rifampicin
and isoniazid are combined together in FDC formulation and the another reason for rapid
degradation is due to hygroscopicty of ethambutol that is present in the four FDC.
By observing the above reasons among all FDC formulations which is packed in
strip package is found to be the best formulation since less amount of rifampicin was
degraded when compared to other formulation and there was no influence of light on
tablets  packed  in  strips.  Hence  the  strip  products  undergo  less  degradation  when
compared to blister packages.
80
       
         SUMMARY
& 
CONCLUSION
                       
SUMMARY AND CONCLUSION
 A salient finding of this study is fixed dose combinations containing rifampicin,
isoniazid,  pyrazinamide  and  ethambutol  stored  in  freezer  (40C)  showed  less
amount of degradation of rifampicin when compared to other temperatures like
300C and 400C with 75%RH.
 This study showed that strip package undergo less degradation when compared to
blister  package  because  strip  packages  show  low  moisture  gain  while  blister
package show high moisture gain. 
 Therefore  manufacturers  should  use  packaging  materials  that  provide  strong
barriers.  
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